Anti-CD25 antibody agents
US11802160B2 · kind B2 · utility
0Cited by
5References
10Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Feb 5, 2020 |
| Grant date | Oct 31, 2023 |
| Priority date | — |
| Expiry date | Feb 5, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2015/8518
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure provides antibody sequences found in antibodies that bind to human CD25. In particular, the present disclosure provides sequences of anti-human CD25 antibodies, which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical composition and methods of treatment, in particular for treating cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.